Key Takeaways for the Industry
• The federal government’s role in cannabis is expanding.
• Rescheduling may create opportunities but also new compliance questions.
• DEA registration is emerging as a critical issue for medical marijuana operators.
• Businesses operating both medical and adult-use programs face unique uncertainty.
• Federal legitimacy may come at the cost of greater federal oversight.
• Important compliance decisions may need to be made before all answers are available.
For years, cannabis businesses primarily answered to state regulators. Now they may have to answer to the DEA.
That reality began taking shape earlier this year when the U.S. Department of Justice moved state-licensed medical marijuana from Schedule I to Schedule III under the Controlled Substances Act. While much of the industry’s attention has focused on the potential financial and operational benefits of rescheduling, a more immediate shift is occurring behind the scenes: the Drug Enforcement Administration is transitioning from an agency associated with cannabis enforcement to one increasingly involved in cannabis regulation.
For cannabis operators, investors, and entrepreneurs, the most important questions are no longer whether federal reform is happening. Federal reform is already underway. The questions now are how those changes will be implemented, what role the DEA will play moving forward, and what businesses should be doing today to prepare.
A Brief Reminder: What Changed?
Most industry participants are already familiar with the headlines. Earlier this year, the DOJ moved state-licensed medical marijuana to Schedule III and separate proceedings continue regarding the broader rescheduling of marijuana. The change represents one of the most significant federal cannabis policy developments in decades and could produce substantial tax and operational benefits for qualifying operators.
But rescheduling is only part of the story. The more immediate development is the federal government’s effort to incorporate state-licensed medical marijuana businesses into an oversight framework that includes DEA registration and compliance obligations.
The DEA Is No Longer Standing on the Sidelines
For much of the modern cannabis industry’s existence, state regulators served as the primary point of contact for operators. Businesses focused on state licensing requirements, state inspections, state compliance obligations, and state enforcement priorities.
That dynamic may be changing. Following the DOJ’s rescheduling order, the DEA began accepting registrations from medical marijuana businesses and requesting information concerning ownership structures, operational procedures, supply chains, inventory controls, and other aspects of business operations.
Cannabis businesses have long operated under complex state regulatory systems. What remains unclear is how those systems will interact with a growing federal regulatory presence and how operators will navigate both simultaneously — especially if there are inconsistencies (e.g., the federal definition of hemp differs from many state definitions which differ among each other). That uncertainty may prove just as significant as the rescheduling decision itself.
More Federal Legitimacy May Bring More Federal Oversight
Many businesses understandably view rescheduling through the lens of reduced restrictions and expanded opportunities. Yet there is another side to the equation.
For operators, increased DEA involvement is not merely a compliance issue. As federal oversight expands, businesses may increasingly be evaluated on the strength of their recordkeeping systems, inventory controls, ownership structures, and operational procedures. These issues can affect financing, investor diligence, acquisitions, and enterprise value. Operators that have historically focused exclusively on state compliance may soon need to consider how their businesses would perform under both state and federal scrutiny.
The industry’s long pursuit of federal legitimacy may come at the cost of greater federal oversight. Federal reform may reduce certain legal burdens while simultaneously introducing new compliance obligations.
Key Questions Facing Cannabis Businesses
The industry generally welcomes greater regulatory clarity. The challenge is that many of the most important questions remain unanswered.
Is DEA Registration Mandatory?
Some regulators have suggested that businesses handling medical marijuana should obtain DEA registration. Others have indicated that operators may continue to function under existing state frameworks. As a result, operators in different jurisdictions are receiving different messages regarding what is expected of them.
Will Registration Become a Gateway to Other Benefits?
Many operators are focused on the potential tax implications associated with Schedule III treatment. Questions remain regarding whether registration status will ultimately play a role in access to important benefits, including potential relief from Section 280E.
What Happens to Businesses Operating Both Medical and Adult-Use Programs?
For many businesses, medical and adult-use operations share personnel, facilities, inventory systems, and compliance infrastructure. If federal regulators ultimately require greater separation, operators may face difficult operational and strategic decisions.
Will DEA Enforcement and Compliance Expectations Be Consistent?
Several industry participants have reported varying experiences among DEA regional offices and inspectors. Until more formal guidance is issued, many operators may find themselves navigating uncertainty while trying to anticipate regulatory expectations.
Could Today’s Registration Process Become Tomorrow’s Compliance Framework?
Is the current registration process merely an administrative step, or is it the foundation for a much larger federal regulatory framework? Businesses would be well served to recognize that federal involvement in cannabis appears to be increasing rather than decreasing.
A New Challenge for Multi-State Operators
The DEA’s evolving role may create unique challenges for multi-state operators and their investors. Cannabis businesses already navigate a patchwork of state laws and licensing regimes. The introduction of a more active federal regulator adds another layer of complexity.
For operators, investors, and regulators alike, the industry is entering largely uncharted territory.
What Cannabis Businesses Should Be Doing Now
Although many questions remain unresolved, operators should not assume they can afford to wait for certainty.
• Review ownership and governance structures with an eye toward potential federal scrutiny.
• Assess whether recordkeeping and inventory controls would satisfy both state and federal regulators.
• Evaluate how medical and adult-use operations are structured and documented.
• Monitor developments involving DEA registration and Section 280E.
• Identify who within the organization is responsible for tracking federal regulatory changes.
Conclusion
The question facing cannabis operators is no longer whether the federal government will become involved in the industry. It already has. The more important question is whether businesses will treat DEA oversight as a future issue or begin preparing for it today. Operators that wait for complete regulatory certainty may find themselves reacting to change, while those that prepare now will be better positioned to capitalize on the opportunities and manage the risks that accompany this next phase of federal cannabis reform.